Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.26 -0.09 (-2.07%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond the surface to discover whether or not Arena Pharmaceuticals could be running out of money. Today we'll do just that, as well as look at ...
Related articles »  
Arena Offers Tease On Belviq And Phentermine (ARNA)
Arena announced that the 12 week study involving 238 patients met the safety endpoints, but the company stopped short of announcing the results of weight loss, opting to save that data for the Obesity Week Conference next week.
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot ...  MarketWatch
Arena Pharma (ARNA) Gains; Reports Results of Investigational Pilot Study of ...  StreetInsider.com (subscription)
Related articles »  
Trader's Buzz: Unilife Corporation (UNIS), Arena Pharmaceuticals (ARNA ...
ARNA shares recently gained $0.01 to $4.36. The stock is down more than 2.22% year-over-year and has lost roughly 24.79% year-to-date.
Pharma Stocks to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Monday said data from phase 3 clinical trials of its obesity drug BELVIQ (lorcaserin HCl) will be presented at the American College of Clinical Pharmacy meeting taking place through Wednesday of this week.
Related articles »  
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
Related articles »  
Belviq Sales Flat - Model Your Expectations (ARNA)
Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS).
Related articles »  
Pfizer Setback Could Help Arena
It was only a month ago that the company received positive indications from the FDA when the regulators agreed to a new label for the drug that was less stringent than the earlier label.
Related articles »  
Sizzling Stock Alert: Novavax, Inc. (NVAX), Arena Pharmaceuticals, Inc.(ARNA ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) disclosed that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ� (lorcaserin HCl) was published in the October issue of Postgraduate Medicine, a peer-reviewed medical ...
Related articles »  
Arena Pharmaceuticals Inc.: Arena Pharmaceuticals Announces Third Quarter ...
SAN DIEGO, Oct. 27, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m.
Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and ...  CNNMoney
Related articles »  
Hot Biotech Round Up: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declared that facts from the stage 3 scientific test program for BELVIQ (lorcaserin HCl) CIV will be launched at the American College of Clinical Pharmacy (ACCP) yearly conference held on last ...
Related articles »